Yutian Chong, MD, PhD

Titles

Chief Physician of Internal Medicine

Doctoral Supervisor

Vice-President, the 3rd Affiliated Hospital of the Sun Yat-sen University

President, Committee on Hepatitis, the Guangdong  Association of Hepatology
President, Infectious Diseases Branch, the Guangdong Physicians Association.

Research Interests

• Liver failure

• Antiviral therapy of chronic hepatitis B

• Long-term standardized follow-up of hepatitis

• Early diagnosis and treatment of hepatocellular carcinoma

• Cholestatic liver disease

Dr Chong's early work concentrates on comprehensive therapy of end-stage liver diseases (especially liver failure) and antiviral therapy post liver transplantation. He focuses on antiviral therapy and long-term standardized follow-up for chronic hepatitis B patients for the past 15 years. Recently, he paid more attention to the prevention, early diagnosis and treatment of HBV-related hepatocellular carcinoma. He and his colleague found a serum microRNA classifier could earlier diagnose or predict preclinical hepatocellular carcinoma, and published this finding on the journal of lancet oncology. Dr Chong is also interested in cholestatic liver disease, including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), benign recurrent intrahepatic cholestasis (BRIC) and progressive familial intrahepatic cholestasis (PFIC).

Education and Experience

1980-1986School of Medicine, the Sun Yat-sen University

1986-present Department of Infectious Diseases, the 3rd Affiliated Hospital of the Sun Yat-sen University

Publications

1.ngxing Huang, Yusheng Jie, Guoli Lin, Hong Shi, Xiangyong Li, Xinhua Li, Yuankai Wu, Yutian Chong*. Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients. Clin Drug Investig. 2016 Mar 18. [Epub ahead of print]

2.ankai Wu, Yusheng Jie, Xiangyong Li, Mingxing Huang, Hong Shi, Shuru Chen, Min Zhang, Yunlong Ao, Fangji Yang, Zhiliang Gao, Guoli Lin, Yutian Chong*. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients. Clin Res Hepatol Gastroenterol. 2016 Apr;40(2):213-20. 

3.ng Shi, Mingxiang Huang, Guoli Lin, Xiangyong Li, Yuankai Wu, Yusheng Jie, Yutian Chong*. Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA. Biomed Res Int. 2016;2016:6725073. doi: 10.1155/2016/6725073. [Epub 2016 Mar 1].

4.e-Jia Lin#, Yutian Chong#, Zhi-Wei Guo#, Chen Xie, Xiao-Jing Yang, Qi Zhang, Sheng-Ping Li, Yujuan Xiong, Yunfei Yuan, Jun Min, Wei-Hua Jia,Yusheng Jie, Min-Shan Chen, Mei-Xian Chen, Jian-Hong Fang, Chunxian Zeng, Yaojun Zhang, Rong-Ping Guo, Yuankai Wu, Guoli Lin, Limin Zheng, Shi-Mei Zhuang. A serum microRNA classifi er for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identifi cation study with a nested case-control study the Lancet Oncology 2015; 16(7):804–815.

5.angyong Li, Xu You , Yusheng Jie, Guoli Lin，Yuankai Wu, Mingxing Huang, Min Zhang, Zhanyi Li, Dongying Xie, Zhiliang Gao, Yutian Chong*. Entecavir combined adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy. American Journal of Therapeutics. 2015 Apr 25 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/25923228

6.ngxing Huang, Yusheng Jie, Hong Shi, Xinhua Li, Xiangyong Li, Yuankai Wu, Guoli Lin, Yutian Chong*. Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China. International Journal of Clinical and Experimental Medicine 2015;8(1):666-673.

7.sheng Jie, Xiangyong Li, Guoli Lin, Yuankai Wu, Xinhua Li, Zhiliang Gao, Yutian Chong*. Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation study. Hepatology International. 2014,8(4):501-507.

8.n Zhang, Fenglan Wang, Yutian Chong, Qiang Tai, Qiyi Zhao, Yubao Zheng, Liang Peng, Shumei Lin and Zhiliang Gao. Liver myofibroblasts from hepatitis B related liver failure patients may regulate natural killer cell function via PGE2. Journal of Translational Medicine; 2014, 12:308.

9.n Zhang, Yinong Ye, Fenglan Wang, Jianyun Zhu, Qiyi Zhao, Yubao Zheng, Yurong Gu, Chan Xie, Zhanlian Huang, Qiang Tai, Yutian Chong and Zhiliang Gao. Liver myofibroblasts up-regulate monocyte CD163 expression via PGE2 during hepatitis B induced liver failure. Journal of Translational Medicine; 2014, 12:60.

10. Zhang, Fenglan Wang, Jianyun Zhu, Yubao Zheng, Qiyi Zhao, Yurong Gu, Qi Zhang, Yutian Chong and Zhiliang Gao. Liver myofibroblasts regulate the phenotype and function of monocytes through soluble factors in cirrhosis. Experimental and Therapeutic Medicine; 2013, 5(1):143-149.

11. Luo, Xiangyong Li, Yuankai Wu, Guoli Lin, Yihua Pang, Xiao Zhang, Yunlong Ao, Zhan Du, Zhixin Zhao, Yutian Chong*. Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life. International Journal of Medical Sciences.2013,Vol,10(4):427-433

Contact

Department of Infectious Diseases

The 3rd Affiliated Hospital of the Sun Yat-sen University

No. 600 Tianhe Road, Tianhe District

Guangzhou, Guangdong, 510630

E-mail: ytchongkyzy@126.com